Literature DB >> 24841650

Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy.

J Z Li1, Z Q Tian2, S N Jiang3, T Feng4.   

Abstract

We conducted a comprehensive study to investigate the role of genes involved in metabolic and transport pathways in response to chemotherapy and clinical outcome of osteosarcoma patients. Genotyping of seven gene polymorphisms was performed on a 384-well plate format on the Sequenom MassARRAY platform in 162 patients with osteosarcoma. We studied the correlation of the seven gene polymorphisms with response to chemotherapy and clinical outcome of patients. Individuals with the ABCB1 TT genotype had a higher probability of responding poorly to chemotherapy, indicated by an odds ratio (OR) of 2.64 (95%CI=1.04-6.83). Similarly, the genotype of GSTP1 GG was significantly associated with improved responses to chemotherapy, indicated by an OR of 3.33 (95%CI=1.26-8.99). The ABCB1 TT and GSTP1 GG genotypes were significantly associated with a shorter overall survival (OS). Our study found that two gene polymorphisms in two transporter genes and one Phase II metabolism enzymes are associated with response to chemotherapy and OS in osteosarcoma patients, suggesting the potential of the two gene polymorphisms as prognostic biomarkers for osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24841650     DOI: 10.4238/2014.April.25.3

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  12 in total

Review 1.  Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.

Authors:  Suoyuan Li; Wei Sun; Hongsheng Wang; Dongqing Zuo; Yingqi Hua; Zhengdong Cai
Journal:  Tumour Biol       Date:  2015-02-11

Review 2.  The pharmacogenomics of osteosarcoma.

Authors:  M Serra; C M Hattinger
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

3.  Establishment and characterization of novel patient-derived osteosarcoma xenograft and cell line.

Authors:  Fusako Kito; Rieko Oyama; Marimu Sakumoto; Mami Takahashi; Kumiko Shiozawa; Zhiwei Qiao; Hiromi Sakamoto; Takeshi Hirose; Nokitaka Setsu; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-06-25       Impact factor: 2.416

4.  ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis.

Authors:  Zifei Zhou; Quanchi Chen; Dongqing Zuo; Hongsheng Wang; Yingqi Hua; Zhengdong Cai
Journal:  Int J Clin Exp Med       Date:  2015-01-15

5.  Apatinib inhibits cell proliferation and migration of osteosarcoma via activating LINC00261/miR-620/PTEN axis.

Authors:  Gang Han; Quanyi Guo; Ning Ma; Wenzhi Bi; Meng Xu; Jinpeng Jia
Journal:  Cell Cycle       Date:  2021-08-23       Impact factor: 5.173

6.  GSTP1 A>G polymorphism and chemosensitivity of osteosarcoma: A meta-analysis.

Authors:  Wu Fengfeng; Ye Ruqing; Xu Juntao
Journal:  Open Med (Wars)       Date:  2016-04-18

Review 7.  Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.

Authors:  Claudia Maria Hattinger; Maria Pia Patrizio; Silvia Luppi; Massimo Serra
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

8.  lncRNA-NEF is downregulated in osteosarcoma and inhibits cancer cell migration and invasion by downregulating miRNA-21.

Authors:  Qinglei Yang; Hongying Yu; Qingshui Yin; Xiaoming Hu; Chengcheng Zhang
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

9.  Association between GSTP1 polymorphisms and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis.

Authors:  Feifei Pu; Fengxia Chen; Songfeng Chen; Baichuan Wang; Jianxiang Liu; Zengwu Shao
Journal:  Onco Targets Ther       Date:  2015-07-23       Impact factor: 4.147

Review 10.  Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.

Authors:  Xueyong Liu; Zhan Zhang; Chunbo Deng; Yihao Tian; Xun Ma
Journal:  Oncotarget       Date:  2017-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.